Tumor Necrosis Factor

FAS

Apo-1 antigen, FASLG receptor, CD antigen CD95

Homo sapiens (Human)

Partial

1713127; 1375228; 7575433; 7533181; 8598453; 8648105; 17336828; 14702039; 15164054; 15489334; 7538908; 10542291; 10535980; 14759258; 15465831; 18691976; 18669648; 19159218; 21109225; 20068231; 21269460; 22171320; 24275569; 8967952; 19118384; 7540117; 8929361; 9028321; 9028957; 9322534; 9787134; 9821419; 10090885; 10515860; 10340403; 9927496; 10620127; 11418480; 20935634

17.6 kDa

Tag-Free

E.Coli

>95% as determined by SDS-PAGE and HPLC.

0.2 μm filtered PBS, pH 7.4 ,lyophilized

Less than 1.0 EU/μg as determined by LAL method.

Fully biologically active when compared to standard. The ED50 as determined by its ability to inhibit the cytotoxicity of Jurkat cells is between 10-15 ug/ml in the presence of 2 ng/ml of rHuFas Ligand.

TNR6_HUMAN

Receptor for TNFSF6/FASLG. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. FAS-mediated apoptosis may have a role in the induction of peripheral tolerance, in the antigen-stimulated suicide of mature T-cells, or both. The secreted isoforms 2 to 6 block apoptosis (in vitro). {ECO:0000269|PubMed:19118384, ECO:0000269|PubMed:7533181}.

RLSSKSVNAQ VTDINSKGLE LRKTVTTVET QNLEGLHHDG QFCHKPCPPG ERKARDCTVN GDEPDCVPCQ EGKEYTDKAH FSSKCRRCRL CDEGHGLEVE INCTRTQNTK CRCKPNFFCN STVCEHCDPC TKCEHGIIKE CTLTSNTKCK EEGSRSN

17-173aa

Cancer